Longboard Pharmaceuticals, Inc.
NASDAQ:LBPH
59.78 (USD) • At close November 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 0 | 0 | 0.008 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 0 | 0.002 | 0.001 | 0.001 | 0.001 | 0.002 | 0.001 | 0.001 | 0.001 | 0.002 | 0.001 | 0.001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit
| 0 | -0.002 | -0.001 | 0.007 | -0.001 | -0.002 | -0.001 | -0.001 | -0.001 | -0.002 | -0.001 | -0.001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit Ratio
| 0 | 0 | 0 | 0.875 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 21.45 | 20.445 | 13.17 | 12.198 | 10.488 | 12.536 | 8.53 | 9.193 | 9.403 | 8.921 | 7.121 | 6.368 | 4.093 | 4.915 | 4.398 | 2.171 | 1.603 | 0.8 | 0.059 |
General & Administrative Expenses
| 6.674 | 5.198 | 4.94 | 3.375 | 3.094 | 3.106 | 3.432 | 2.534 | 2.481 | 2.646 | 2.499 | 2.426 | 2.262 | 2.072 | 1.305 | 7.938 | 0.947 | 0.767 | 0.115 |
Selling & Marketing Expenses
| 0 | 0 | -0.001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 6.674 | 5.198 | 4.939 | 3.375 | 3.094 | 3.106 | 3.432 | 2.534 | 2.481 | 2.646 | 2.499 | 2.426 | 2.262 | 2.072 | 1.305 | 7.938 | 0.947 | 0.767 | 0.115 |
Other Expenses
| 0 | -0.047 | -0.009 | -0.027 | -0.014 | -0.017 | -0.01 | -0.009 | 0.001 | 0.033 | -0.009 | -0.003 | -0.013 | -0.006 | 0 | 0 | 0 | 0 | 0 |
Operating Expenses
| 28.124 | 25.643 | 18.109 | 15.573 | 13.582 | 15.642 | 11.962 | 11.727 | 11.884 | 11.567 | 9.62 | 8.794 | 6.355 | 6.987 | 5.703 | 10.109 | 2.55 | 1.567 | 0.174 |
Operating Income
| -28.124 | -25.643 | -18.11 | -15.573 | -13.582 | -15.642 | -11.962 | -11.727 | -11.884 | -11.567 | -9.62 | -8.794 | -6.355 | -6.987 | -5.703 | -10.109 | -2.55 | -1.567 | -0.174 |
Operating Income Ratio
| 0 | 0 | 0 | -1,946.625 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 3.584 | 3.858 | 3.124 | 0.54 | 0.648 | 0.643 | 0.506 | 0.382 | 0.288 | 0.16 | 0.023 | 0.021 | 0.01 | 0.007 | 0.004 | 0 | 0 | 0 | 0 |
Income Before Tax
| -24.54 | -21.785 | -14.986 | -15.033 | -12.934 | -14.999 | -11.456 | -11.345 | -11.596 | -11.407 | -9.597 | -8.773 | -6.345 | -6.98 | -5.699 | -10.109 | -2.55 | -1.567 | -0.174 |
Income Before Tax Ratio
| 0 | 0 | 0 | -1,879.125 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| -24.54 | -0.002 | -0.042 | -0.567 | -0.001 | -0.66 | -0.506 | -0.382 | -0.288 | -0.127 | -0.032 | -0.025 | -6.378 | -7 | -5.703 | -10.109 | -2.55 | -1.567 | -0.174 |
Net Income
| -24.54 | -21.785 | -14.986 | -15.033 | -12.934 | -14.999 | -10.95 | -10.963 | -11.308 | -11.407 | -9.597 | -8.773 | -6.345 | -6.98 | -5.699 | -10.109 | -2.55 | -1.567 | -0.174 |
Net Income Ratio
| 0 | 0 | 0 | -1,879.125 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS
| -0.63 | -0.56 | -0.42 | -0.63 | -0.55 | -0.65 | -0.54 | -0.64 | -0.66 | -0.67 | -0.56 | -0.52 | -0.38 | -0.41 | -0.34 | -0.6 | -0.15 | -0.093 | -0.01 |
EPS Diluted
| -0.63 | -0.56 | -0.42 | -0.63 | -0.55 | -0.65 | -0.54 | -0.64 | -0.66 | -0.67 | -0.56 | -0.52 | -0.38 | -0.41 | -0.34 | -0.6 | -0.15 | -0.093 | -0.01 |
EBITDA
| -28.124 | -25.641 | -18.109 | -15.572 | -13.581 | -15.64 | -11.961 | -11.726 | -11.883 | -11.565 | -9.619 | -8.794 | -6.355 | -6.987 | -5.703 | -10.109 | 0 | -1.567 | 0 |
EBITDA Ratio
| 0 | 0 | 0 | -1,946.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |